Additionally, it is conceivable that reversion mutations that restore the open reading frame of BRCA1, as has been documented for BRCA2, may also confer resistance to PARP inhibitor in breast and ovarian cancers expressing BRCA1 mutation [2, 8, 44]. Here, PARP1 is linked to ovarian carcinoma.